Immunosuppressive Tumor Microenvironment and Immunotherapy of Epstein-Barr Virus-Associated Malignancies

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2022 May 28

PMID 35632758

Authors

Xueyi Zheng

Yuhua Huang

Kai Li

Rongzhen Luo

Muyan Cai

Jingping Yun

Affiliations

Soon will be listed here.

Abstract

The Epstein-Barr virus (EBV) can cause different types of cancer in human beings when the virus infects different cell types with various latent patterns. EBV shapes a distinct and immunosuppressive tumor microenvironment (TME) to its benefit by influencing and interacting with different components in the TME. Different EBV-associated malignancies adopt similar but slightly specific immunosuppressive mechanisms by encoding different EBV products to escape both innate and adaptive immune responses. Strategies reversing the immunosuppressive TME of EBV-associated malignancies have been under evaluation in clinical practice. As the interactions among EBV, tumor cells, and TME are intricate, in this review, we mainly discuss the epidemiology of EBV, the life cycle of EBV, the cellular and molecular composition of TME, and a landscape of different EBV-associated malignancies and immunotherapy by targeting the TME.

Citing Articles

Exploring the role of Epstein-Barr virus infection on the clinical features and survival in locally advanced cervical cancer: a retrospective cohort study.

Castro-Uriol D, Vera J, Valcarcel B, Lopez-Ilasaca M, Yabar A, Camara A Front Oncol. 2025; 14():1522244.

PMID: 39777354 PMC: 11703704. DOI: 10.3389/fonc.2024.1522244.

Altered ACE2 and interferon landscape in the COVID-19 microenvironment correlate with the anti-PD-1 response in solid tumors.

Subbarayan K, Al-Samadi A, Schafer H, Massa C, Salo T, Biehl K Cell Mol Life Sci. 2024; 81(1):473.

PMID: 39625479 PMC: 11615173. DOI: 10.1007/s00018-024-05520-9.

Immune Modulation by Epstein-Barr Virus Lytic Cycle: Relevance and Implication in Oncogenesis.

Todorovic N, Ambrosio M, Amedei A Pathogens. 2024; 13(10).

PMID: 39452747 PMC: 11510492. DOI: 10.3390/pathogens13100876.

N6-methyladenosine methylation regulates the tumor microenvironment of Epstein-Barr virus-associated gastric cancer.

Zhang Y, Zhou F, Zhang M, Feng L, Guan J, Dong R World J Gastrointest Oncol. 2024; 16(6):2555-2570.

PMID: 38994134 PMC: 11236235. DOI: 10.4251/wjgo.v16.i6.2555.

The Potential Role of Virus Infection in the Progression of Thyroid Cancer.

Wu Y, Jiang T, Su Y, Mei L, Sun T, Li Y World J Oncol. 2024; 15(3):382-393.

PMID: 38751704 PMC: 11092407. DOI: 10.14740/wjon1830.

References

Green M, Rodig S, Juszczynski P, Ouyang J, Sinha P, ODonnell E . Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res. 2012; 18(6):1611-8. PMC: 3321508. DOI: 10.1158/1078-0432.CCR-11-1942. View

Que Y, Wang J, Zhu J, Li N, Huang J, Lu S . Combination Therapy With Anti-PD-1 or PD-1 Antibody Alone in Asian Pediatric Patients With Relapsed or Refractory Cancer. Front Immunol. 2021; 12:647733. PMC: 8290852. DOI: 10.3389/fimmu.2021.647733. View

Nanbo A, Kawanishi E, Yoshida R, Yoshiyama H . Exosomes derived from Epstein-Barr virus-infected cells are internalized via caveola-dependent endocytosis and promote phenotypic modulation in target cells. J Virol. 2013; 87(18):10334-47. PMC: 3753980. DOI: 10.1128/JVI.01310-13. View

Lee S, Tierney R, Thomas W, Brooks J, Rickinson A . Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy. J Immunol. 1997; 158(7):3325-34. View

Shah K, Stewart S, Wei W, Woodman C, ONeil J, Dawson C . The EBV-encoded latent membrane proteins, LMP2A and LMP2B, limit the actions of interferon by targeting interferon receptors for degradation. Oncogene. 2009; 28(44):3903-14. PMC: 2774296. DOI: 10.1038/onc.2009.249. View

Iwakiri D . Epstein-Barr Virus-Encoded RNAs: Key Molecules in Viral Pathogenesis. Cancers (Basel). 2014; 6(3):1615-30. PMC: 4190559. DOI: 10.3390/cancers6031615. View

Munz C, Bickham K, Subklewe M, Tsang M, Chahroudi A, Kurilla M . Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. J Exp Med. 2000; 191(10):1649-60. PMC: 2193162. DOI: 10.1084/jem.191.10.1649. View

Epstein A . Burkitt lymphoma and the discovery of Epstein-Barr virus. Br J Haematol. 2012; 156(6):777-9. DOI: 10.1111/j.1365-2141.2011.09008.x. View

Ressing M, van Leeuwen D, Verreck F, Gomez R, Heemskerk B, Toebes M . Interference with T cell receptor-HLA-DR interactions by Epstein-Barr virus gp42 results in reduced T helper cell recognition. Proc Natl Acad Sci U S A. 2003; 100(20):11583-8. PMC: 208801. DOI: 10.1073/pnas.2034960100. View

10.

Vetsika E, Koukos A, Kotsakis A . Myeloid-Derived Suppressor Cells: Major Figures that Shape the Immunosuppressive and Angiogenic Network in Cancer. Cells. 2019; 8(12). PMC: 6953061. DOI: 10.3390/cells8121647. View

11.

Iwakiri D, Takada K . Role of EBERs in the pathogenesis of EBV infection. Adv Cancer Res. 2010; 107:119-36. DOI: 10.1016/S0065-230X(10)07004-1. View

12.

Hussein K, Maecker-Kolhoff B, Donnerstag F, Laenger F, Kreipe H, Jonigk D . Epstein-Barr virus-associated smooth muscle tumours after transplantation, infection with human immunodeficiency virus and congenital immunodeficiency syndromes. Pathobiology. 2013; 80(6):297-301. DOI: 10.1159/000351326. View

13.

Cristescu R, Lee J, Nebozhyn M, Kim K, Ting J, Wong S . Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015; 21(5):449-56. DOI: 10.1038/nm.3850. View

14.

Ouyang J, Juszczynski P, Rodig S, Green M, ODonnell E, Currie T . Viral induction and targeted inhibition of galectin-1 in EBV+ posttransplant lymphoproliferative disorders. Blood. 2011; 117(16):4315-22. DOI: 10.1182/blood-2010-11-320481. View

15.

Banchereau J, Steinman R . Dendritic cells and the control of immunity. Nature. 1998; 392(6673):245-52. DOI: 10.1038/32588. View

16.

Chen L, Wang L, Tsang N, Ojcius D, Chen C, OuYang C . Tumour inflammasome-derived IL-1β recruits neutrophils and improves local recurrence-free survival in EBV-induced nasopharyngeal carcinoma. EMBO Mol Med. 2012; 4(12):1276-93. PMC: 3531603. DOI: 10.1002/emmm.201201569. View

17.

Xie Y, Pittaluga S, Jaffe E . The histological classification of diffuse large B-cell lymphomas. Semin Hematol. 2015; 52(2):57-66. PMC: 4374126. DOI: 10.1053/j.seminhematol.2015.01.006. View

18.

Orimo A, Gupta P, Sgroi D, Arenzana-Seisdedos F, Delaunay T, Naeem R . Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005; 121(3):335-48. DOI: 10.1016/j.cell.2005.02.034. View

19.

Yamamura Y, Asai N, Enomoto A, Kato T, Mii S, Kondo Y . Akt-Girdin signaling in cancer-associated fibroblasts contributes to tumor progression. Cancer Res. 2015; 75(5):813-23. DOI: 10.1158/0008-5472.CAN-14-1317. View

20.

Cesarman E . Gammaherpesviruses and lymphoproliferative disorders. Annu Rev Pathol. 2013; 9:349-72. DOI: 10.1146/annurev-pathol-012513-104656. View